Erika Jaramillo, APRN
Family · Little Rock, ARNPI 1518389709
Payments from drug & device makers
Across 387 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$744
- GSK$584
- Novo Nordisk$535
- AstraZeneca$439
- Pfizer$420
- Lilly USA, LLC$412
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,224100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $744 |
| GSK | 45 | $584 |
| Novo Nordisk | 33 | $535 |
| AstraZeneca | 17 | $439 |
| Pfizer | 26 | $420 |
| Lilly USA, LLC | 30 | $412 |
| Astellas Pharma US Inc | 18 | $314 |
| Bayer | 14 | $251 |
| Boehringer Ingelheim | 16 | $248 |
| Amgen | 16 | $245 |
| Johnson & Johnson | 14 | $224 |
| Biohaven Pharmaceuticals, Inc. | 11 | $155 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $149 |
| Abbott | 9 | $148 |
| Merck | 10 | $144 |
| Phathom Pharmaceuticals, Inc. | 9 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $133 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $133 |
| Dexcom, Inc. | 7 | $114 |
| Teva Pharmaceuticals USA, Inc. | 7 | $111 |
| Exact Sciences | 4 | $69 |
| E.r. Squibb & Sons, L.L.C. | 5 | $69 |
| Dynavax Technologies Corporation | 4 | $66 |
| Mylan Specialty L.p. | 3 | $65 |
| Novartis | 3 | $50 |
| Eisai Inc. | 3 | $48 |
| Inspire Medical Systems, Inc. | 2 | $37 |
| Bausch Health US, LLC | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Esperion Therapeutics, Inc. | 2 | $26 |
| Averitas Pharma Inc. | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,224 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 78 | $83,254 |
| MounjaroTirzepatide | 77 | $81,557 |
| OzempicSemaglutide | 44 | $77,428 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $53,631 |
| JardianceEmpagliflozin | 51 | $50,970 |
| XareltoRivaroxaban | 21 | $30,807 |
| ProliaDenosumab | 16 | $27,056 |
| Repatha SureclickEvolocumab | 29 | $21,515 |
| FarxigaDapagliflozin Propanediol | 21 | $21,373 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $18,714 |
| TrulicityDulaglutide | 15 | $14,894 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $14,741 |
| JanuviaSitagliptin Phosphate | 13 | $14,103 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $10,815 |
| BelsomraSuvorexant | 13 | $7,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $412 | $96,45192 claims |
| PfizerEliquis | $420 | $83,25478 claims |
| Novo NordiskOzempic | $535 | $77,42844 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $584 | $67,24587 claims |
| Boehringer IngelheimJardiance | $248 | $50,97051 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $439 | $43,74458 claims |
| Johnson & JohnsonXarelto | $224 | $30,80721 claims |
| AmgenProlia | $245 | $27,05616 claims |
| MerckJanuvia, Belsomra | $144 | $21,43326 claims |
| AbbVieSynthroid | $744 | $1,73627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.
Other family in Little Rock
- Anthony EcholsLittle Rock$25K
- Michael StirlingLittle Rock$23K
- Laura BarganierLittle Rock$17K
- Emily AllenLittle Rock$14K
- Brandy EasonLittle Rock$13K
- Matthew TaylorLittle Rock$10K
- Collene RogersLittle Rock$9K
- Morgan BittengleLittle Rock$9K
- Melissa BaldwinLittle Rock$8K
- Leah CarringtonRogers$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.